Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences establishes scientific advisory board

The board will provide scientific oversight and strategic advice to Metrion

Contract research organisation and drug discovery business Metrion Biosciences has established a scientific advisory board, which will provide strategic scientific guidance to the company.

The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

Dr Reynolds has served in numerous positions at Merck, Lundbeck and Pfizer.

Dr Tom Colatsky also joins the board following over 30 years of drug discovery experience, including seven years in senior US Food and Drug Admistration positions.

The board will also comprise of Professor Annette Dolphin, Professor Chris Denning and Marc Rogers, who is currently chief scientific officer at Metrion.

20th February 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics